Brief: Radius Health And Teijin Pharma Entered Into Amendment To License & Development Agreement

Radius Recycling

02/08/2022 21:38

Aug 2 (Reuters) - Radius Health Inc  RDUS.O :
    * RADIUS HEALTH INC - ON JULY 28, 2022, CO AND TEIJIN PHARMA
ENTERED INTO AMENDMENT TO LICENSE & DEVELOPMENT AGREEMENT
    * RADIUS HEALTH INC - LDA HAS BEEN AMENDED BY AMENDMENT TO
REMOVE
REFERENCES TO JOINT COMMERCIALIZATION OPPORTUNITY
    * RADIUS HEALTH INC - LDA HAS BEEN AMENDED TO WAIVE ROYALTY
ON NET
SALES OF ANY ABALOPARATIDE-SC PURCHASED BY TEIJIN THROUGH
COMMERCIAL SUPPLY AGREEMENT
    * RADIUS HEALTH INC - AMENDMENT DOES NOT HAVE ANY IMPACT ON
ROYALTIES OWED ON SALES OF ABALOPARATIDE-SC NOT PURCHASED
THROUGH CSA
    * RADIUS HEALTH INC - AMENDMENT ALSO PROVIDES THAT LDA MAY
BE
TERMINATED BY EITHER PARTY DUE TO A MATERIAL BREACH OF CSA BY
OTHER PARTY

Source text for Eikon: [https://bit.ly/3POcZTb]
Further company coverage:  RDUS.O 

 ((Reuters.Briefs@thomsonreuters.com;))